Darren Smyth, Richard Croker, and Ben Goldacre explain the arguments over the patent case and explore the wider implications for the NHS and drug development
Pregabalin: what the patent litigation means for doctors and drug companies
- Authors:
Ben Goldacre
Darren Smyth
Richard Croker - Posted:
7 June 2018
- Citation:
Smyth, D., Croker, R., & Goldacre, B. (2018). Pregabalin. BMJ, k2318.
- Tags:
More in OpenPrescribing
NHS England Medicines Optimisation Opportunities - A new dashboard on OpenPrescribing
13 Sep, 2023
[PRE-PRINT] Data-driven identification of potentially successful intervention implementations: a proof of concept using five years of opioid prescribing data from over 7000 practices in England
29 Jun, 2023
Data-Driven Identification of Unusual Prescribing Behavior: Analysis and Use of an Interactive Data Tool Using 6 Months of Primary Care Data From 6500 Practices in England
19 Apr, 2023
OpenPrescribing in the media - recent highlights
19 Apr, 2023
Introduction to the Clinical Informatics Team
4 Apr, 2023
Identifying over prescribed chemicals: a data-driven approach to mining prescription data
4 Jan, 2023
Identifying Patterns of Clinical Interest in Clinicians' Treatment Preferences: Hypothesis-free Data Science Approach to Prioritizing Prescribing Outliers for Clinical Review
20 Dec, 2022